Imunon (NASDAQ:IMNN) Releases Quarterly Earnings Results, Beats Expectations By $0.38 EPS

Imunon (NASDAQ:IMNN) issued its quarterly earnings data on Tuesday. The company reported ($0.84) earnings per share for the quarter, topping the consensus estimate of ($1.22) by $0.38, FiscalAI reports.

Here are the key takeaways from Imunon’s conference call:

• Imunon said OVATION 3 is progressing well, with management reiterating that enrollment remains on track and that the company expects to randomize about 80 patients by the end of Q1 2027.
• The company highlighted strong Phase II results for IMNN-001, including a 14.7-month median overall survival benefit in OVATION 2, which management believes supports the drug’s potential in frontline ovarian cancer.
• Management emphasized that the Phase III trial is designed around overall survival as the primary endpoint, with two planned interim analyses and a path that could support a single pivotal-trial BLA filing if successful.
• Imunon acknowledged the challenging biotech funding environment and said it is pursuing bridge financing and cost controls to extend runway while trying to minimize dilution.
• First-quarter 2026 operating cash use was $4.0 million, up from $2.8 million a year ago, largely due to OVATION 3 startup costs, while R&D and G&A expenses were roughly stable year over year.

Imunon Stock Down 0.7%

IMNN traded down $0.02 during trading on Tuesday, reaching $2.71. 14,895 shares of the stock traded hands, compared to its average volume of 75,090. The stock has a market capitalization of $10.79 million, a PE ratio of -0.34 and a beta of 2.04. The stock’s 50-day moving average is $3.00 and its 200 day moving average is $3.49. Imunon has a 12 month low of $2.52 and a 12 month high of $41.22.

Institutional Trading of Imunon

An institutional investor recently raised its position in Imunon stock. DRW Securities LLC raised its position in shares of Imunon, Inc. (NASDAQ:IMNN) by 6.9% during the fourth quarter, according to its most recent disclosure with the Securities and Exchange Commission. The fund owned 58,830 shares of the company’s stock after acquiring an additional 3,803 shares during the quarter. DRW Securities LLC owned about 1.92% of Imunon worth $224,000 as of its most recent SEC filing. 4.47% of the stock is owned by hedge funds and other institutional investors.

Analysts Set New Price Targets

A number of analysts have commented on the stock. Weiss Ratings reaffirmed a “sell (e+)” rating on shares of Imunon in a research report on Tuesday, April 21st. Maxim Group set a $10.00 price target on shares of Imunon and gave the company a “buy” rating in a research report on Friday, April 17th. One analyst has rated the stock with a Buy rating, one has issued a Hold rating and one has assigned a Sell rating to the stock. According to MarketBeat.com, Imunon presently has a consensus rating of “Hold” and a consensus target price of $132.50.

Imunon Company Profile

Imunon, Inc, a clinical-stage biotechnology company, engages in the development of immunotherapies and vaccines to treat cancer and infectious diseases. The company’s lead clinical program IMNN-001, a DNA-based immunotherapy for the localized treatment of ovarian cancer that is in Phase II clinical development. Its preclinical stage products include IMNN-101, a COVID-19 booster vaccine; IMNN-102 for the treatment of Lassa virus; and IMNN-201, a Trp2 tumor associated antigen cancer vaccine in melanoma.